Recent News

AACR COVID-19: Balancing Risks and Benefits of Surgery for Breast Cancer

FDA Accepts Two Applications for Pembrolizumab in Triple-Negative Breast Cancer

FDA Approves Breast Cancer Companion Diagnostic for Trastuzumab Therapy

AACR COVID-19: Adjustments in Use of CDK4/6 Inhibitors for Metastatic Breast Cancer

Collaborative Palliative Care Intervention for Women With Metastatic Breast Cancer

AACR COVID-19: National Survey of Patient Concerns Regarding Breast Cancer

AACR COVID-19: Recent Trends in Screening for Breast Cancer

BYLieve Trial Supports Use of Alpelisib Plus Fulvestrant for Some Breast Cancers

AACR II: Six New Risk Loci for Breast Cancer Identified in Women of African Ancestry

3-Year TRAIN-2 Update on Neoadjuvant Therapy for HER2-Positive Breast Cancer

AACR II: ARTEMIS Trial of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer

Can Artificial Intelligence Improve the Accuracy of Screening Mammography Assessment?

Biomarker-Based Update on Neoadjuvant Letrozole With or Without Ribociclib

Neoadjuvant Endocrine Therapy for Locally Advanced Breast Cancer

AACR II: Adding Interferon-Gamma to Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer

Combining IL-7 With Pembrolizumab in Metastatic Triple-Negative Breast Cancer

Subcutaneous Combination Therapy Approved by FDA for HER2-Positive Breast Cancer

AACR II: Study Finds Race-Based Survival Differences in Triple-Negative Breast Cancer

First-in-Human Clinical Trial of Microsurgery Robot to Treat Breast Cancer–Related Lymphedema

ASCO20: Tucatinib Combination Therapy for Breast Cancer With Brain Metastases

ASCO20: KEYNOTE-355 Trial of Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer

ASCO20: Does Adding Trastuzumab to Radiotherapy Decrease Recurrence of Breast Cancer?

ASCO20: Which Women With HER2-Positive Early Breast Cancer May Avoid Chemotherapy?

ASCO20: Adding Veliparib to Cisplatin for Select Metastatic Triple-Negative Breast Cancers

ASCO20: MINDACT Update Supports Longer-Term Use of MammaPrint in Clinical Decision-Making

ASCO20: Evaluating Palbociclib Plus Fulvestrant or Letrozole in Metastatic Breast Cancer

ASCO20: Biomarker Expression and Outcomes After Adjuvant Treatment in Breast Cancer

ASCO20: Can Local Therapy Improve Survival in Newly Diagnosed Advanced Breast Cancer?

ASCO20: Adding T-DM1 to Targeted Therapy for High-Risk Early Breast Cancer

ASBrS 2020: Cosmetic Outcomes With Breast-Conserving Therapy

ASBrS 2020: Is Age Associated With the Presentation of Aggressive Breast Cancer?

Therapeutic Nanoparticles for Primary and Metastatic Breast Tumors

Cardiac Dysfunction Related to Breast Cancer Treatment

Single-Cell RNA Sequencing Suggests Oxidative Phosphorylation May Promote Breast Cancer Metastasis

Radiotherapy-Induced Tumors and Li-Fraumeni Syndrome in Patients With Breast Cancer

AACR 2020: Talazoparib Versus Chemotherapy in HER2-Negative Advanced Breast Cancer

DDW 2020: One-Stop Multicancer Screening Program

AACR 2020: Can Fasting Enhance Endocrine Therapy in Breast Cancer?

AACR 2020: Combination Immunotherapy for Triple-Negative Breast Cancer

Does High Fiber Consumption Reduce the Risk of Breast Cancer?

AACR 2020: Lapatinib-Based First-Line Treatment in Metastatic Breast Cancer

TUBB3 Gene Expression: Prognostic Biomarker for Breast Cancer Stage?

Racial Disparity in Clinical Trials of Immunotherapeutics for Breast Cancer

Antibody-Drug Conjugate Receives FDA Approval in Metastatic Triple-Negative Breast Cancer

Consortium Offers Breast Cancer Treatment Recommendations During COVID-19 Pandemic

FDA Approves Tucatinib in Combination Therapy for Metastatic Breast Cancer

SGO 2020: For BRCA-Mutation Carriers, Breast Cancer May Follow Ovarian Cancer

ACC 2020: Can Statins Lower the Rate of Heart Failure After Breast Cancer Treatment?

Improving Patient Care and Self-Management Pathways for Breast Cancer: The 4R Model

ACC 2020: Potential Biomarker of Cardiac Dysfunction in Patients Treated for Breast Cancer

Breast Cancer Treatment Outcomes Across Racial Subgroups: Talazoparib Versus Chemotherapy

Androgen Receptor Agonism in Estrogen Receptor–Positive Breast Cancer

Type 2 Diabetes and Recurrence of Breast Cancer in Older Women

Trastuzumab Biosimilar Receives FDA Approval of Multidose Vial

Predicting Residual Breast Cancer After Neoadjuvant Chemotherapy

TAT 2020: Predictive Biomarker for FGFR Inhibitors in Breast Cancer

Digital Breast Tomosynthesis Versus Digital Mammography: Long-Term Outcomes

TAT 2020: TTK Inhibitor Plus Paclitaxel in Advanced HER2-Negative Breast Cancer

ASCO and CAP Issue Guideline Update on Endocrine Receptor Testing in Breast Cancer

MINDACT Trial of Adjuvant Chemotherapy for Early Luminal Breast Cancer: Does Age Matter?

10-Year Follow-up on Anastrozole in Prevention of Breast Cancer

Neratinib Plus Capecitabine Approved by FDA in HER2-Positive Metastatic Breast Cancer

FDA Accepts BLA for Fixed-Dose Combination Therapy for HER2-Positive Breast Cancer

Physical Activity and Quality of Life After Radiation Therapy for Breast Cancer

Estrogen vs Estrogen Plus Progestin Use in Postmenopausal Women

Tucatinib Receives FDA Priority Review in HER2-Positive Breast Cancer

10-Year Findings With Letrozole in Hormone Receptor–Positive Breast Cancer